Vapes, Pregnancy, and Your Brain's Hidden Autopilot

Your Teen's 'Nicotine-Free' Vape May Contain Something Worse

The words 'nicotine-free' on a vaping product may mean less than you think — and new rat data suggests the replacements aren't benign.

Think of a candy bar relabelled 'sugar-free' that secretly contains a different sweetener — one nobody has properly tested, and that might actually be stronger than the original. That's roughly the situation with two chemicals turning up in 'nicotine-free' vaping products: 6-methyl nicotine (6MN) and nicotinamide (NAM). 6MN is structurally almost identical to nicotine. Researchers studying adolescent rats found it may bind even more tightly to the same nicotinic receptors — the molecular locks in the brain that nicotine normally fits. After exposing young rats to these analogues, the team tested reward sensitivity using cocaine as a chemical probe of the brain's reward circuitry. What they found was altered responsiveness: the brain's reward system had been primed differently by the analogue exposure. Worse, some NAM-labelled products were found to contain undisclosed 6MN — meaning users don't even know what they're actually inhaling. Why does this matter for mental health? Adolescence is when the brain's reward wiring is most plastic — still being assembled. Disrupting that process may leave traces that show up years later as addiction vulnerability or emotional dysregulation. These chemicals are currently unregulated in most markets, and they're in products actively marketed to young people as the safe alternative. The catch — and it's a real one — is that this is rat data. Adolescent rats and adolescent humans share biology, but they're not the same. The researchers found a change in reward sensitivity, not a direct link to mental illness. That's one step in a longer chain. Consider this early-stage signal requiring urgent regulatory attention, not a confirmed diagnosis of harm.

Eight in Ten Pregnant People Using Cannabis Say Mental Health Is the Reason

Of all the reasons people use cannabis during pregnancy, the most common one — by far — is mental health.

Here is a number worth sitting with: 83%. That is the share of pregnant people who reported using cannabis and cited mental health as a motivation, according to a descriptive analysis of US Pregnancy Assessment Monitoring System data covering 2017 to 2021. Not morning sickness. Not pain. Mental health. Gastrointestinal symptoms came second, at 77%. Pain relief was third, at 49%. The motivations overlap — the same person often reported multiple reasons — but mental health sat at the top of the list by a meaningful margin. Think of it like reaching for a glass of wine on an extremely difficult evening when you've already tried every other thing you know. You're not doing it carelessly. You're doing it because the gap between what you need and what's available feels impossible. Pregnant people are frequently told to stop or taper antidepressants and anti-anxiety medications due to fetal safety concerns, leaving them with few perceived options. Cannabis fills that gap, whether we're comfortable with that or not. If the majority of prenatal cannabis use is driven by unmet mental health need, then the story isn't really about cannabis — it's about a failure of care access. The catch is substantial. This is self-reported survey data, which means people may underreport use or conflate motivations. The study does not track outcomes — we don't know whether the cannabis helped, whether it harmed the fetus, or whether it made the mental health situation better or worse. What this data does is describe a pattern. It is a mirror, not a prescription.

Scientists Watched Dopamine React in Real Time as Humans Made Decisions

Using electrodes already inside patients' brains, researchers watched dopamine move in real time — and found it follows an older set of rules than we assumed.

This one required some luck to even run. The researchers used depth electrodes already implanted in patients' brains for clinical reasons — typically epilepsy monitoring — to measure dopamine fluctuations in the anterior cingulate cortex (ACC), a region involved in decision-making and conflict, in real time. That kind of direct, sub-second measurement in a living, conscious human brain is extraordinarily rare. The finding: dopamine doesn't just track whether you made the right learned choice. It also tracks whether your gut instinct and the task were pointing you in the same direction. Think about learning to drive. When the instructor says 'turn right' and you were already planning to turn right, everything flows. When they say 'go straight' but every instinct says 'turn,' something inside resists. The dopamine signal the team recorded was stronger when the required action — act or hold back — matched what the brain's older, automatic Pavlovian system was already expecting. When instinct and task instruction conflicted, the dopamine response weakened. Pavlovian biases are the brain's pre-programmed tendencies: approach reward, avoid threat, regardless of what you've been taught. Most of us know we have them. What this study shows is that they leave a measurable fingerprint in dopamine chemistry, in real time, in humans. Why does this matter for mental health? The ACC is directly implicated in depression and anxiety. If we can characterise how dopamine encodes this tug-of-war between habit and intention, we get a more precise map of what's going wrong in those conditions — and potentially better targets for treatment. The catch: sample sizes in implanted-electrode research are necessarily small, and I've simplified the Pavlovian bias concept here. The paper is not saying instinct overrides learning — it's saying both systems contribute to the dopamine signal simultaneously, which is the more nuanced and interesting claim.

Three stories, one thread: people are navigating broken systems with tools that weren't designed for the job — and the biology is responding accordingly. Adolescents inhale unregulated chemicals because regulatory frameworks haven't caught up with an industry that relabels everything as safe. Pregnant people self-medicate for mental distress because the gap between what they need and what medicine offers them safely is real and large. And underneath both of those human situations, the brain itself is running two competing programs at once — one that learns new rules, one that instinctively reacts to old ones — their conflict visible in the very chemical we associate with motivation and well-being. Mental health isn't just about therapy sessions and prescriptions. It's about what's in the air, who gets access to care, and how well we understand the wiring. Today's three papers each pull at a different thread of the same problem. None of them is solved. All of them are urgent.

On the vaping front, watch for any FDA enforcement actions on novel nicotine analogues — the regulatory gap on 6MN-containing products is well-documented and pressure is building. On prenatal cannabis, the critical open question remains outcomes: does it help, does it harm, and for whom? No controlled trial has answered that directly, and one would be very hard to run ethically. For the dopamine findings, the bottleneck is replication — which means waiting for more patients with implanted electrodes to consent to research tasks. That is, by nature, a slow process.

• Wikipedia: Nicotinic acetylcholine receptors — what nicotine and its analogues actually bind to
• Wikipedia: Dopamine — a clear primer on the chemical at the centre of story three
• Wikipedia: Anterior cingulate cortex — the brain region where the dopamine measurements were taken